In GIST, intra- and inter-lesional heterogeneity of resistance mechanisms is common, and multiple, independent secondary c-Kit mutations occur in GIST patients progressing on imatinib therapy [16, 17]. This evidence concerns the gene KIT and gastrointestinal stromal tumor.